ESCITALOPRAM’S EFFICACY IN TREATING ORGANIC DEPRESSIVE DISORDER ASSOCIATED WITH CEREBROVASCULAR DISEASES


Cite item

Full Text

Abstract

An open-label 6-week trial of the escitalopram’s efficacy in treating depressive disorders associated with cerebrovascular diseases was conducted in 38 patients aged 54-73 years. The improvement was determined in the form of statistically significant amelioration of the patients’ signs (CGI) and reduction of the depressive disorders (MADRS) starting from the second week of treatment. In a 6-week period 77,8 % of the patients responded to the therapy whereas, 58,3 % - reached the state of remission. Escitalopram can be recommended for the organic depressive disorder treatment.

About the authors

Aleksey A Pribytkov

Penza institution of advanced medical studies of the Ministry of Public Health of Russian Federation

Email: pribytkov@bk.ru
440060, Penza, Stasova street, 8а

References

  1. Кудрина П.И., Арьев А.Л., Титков Ю.С. Депрессивные расстройства при сосудистых заболеваниях головного мозга у пациентов пожилого и старческого возраста // Успехи геронтологии. 2012. № 2. С. 290-292.
  2. Оганов Р.Г., Ольбинская Л.И., Смулевич А.Б. и др. Депрессии и расстройства депрессивного спектра в общемедицинской практике / Результаты программы КОМПАС // Кардиология. 2004. № 1. С. 48-54.
  3. Хасанова Д.Р., Житкова Ю.В. Применение эсциталопрама для профилактики синдрома депрессии и когнитивных нарушений в остром периоде инсульта // Неврология, нейропсихиатрия, психосоматика. 2013. № 2. С. 16-22.
  4. Alexopoulos G.S., Meyers B.S., Young R.C. et al. «Vascular depression» hypothesis // Arch. Gen. Psychiatry. 1997. Vol. 54, № 10. P. 915-922.
  5. Broomfield N.M., Quinn T.J., Abdul-Rahim A.H. et al. Depression and anxiety symptoms post-stroke/TIA: prevalence and associations in cross-sectional data from a regional stroke registry // BMC Neurol. 2014. Vol. 14. P. 198.
  6. Cattaneo A., Bocchio-Chiavetto L., Zanardini R. et al. Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment // Int. J. Neuropsychopharmacol. 2010. Vol. 13. № 1. P. 103-108.
  7. Chollet F. Selective serotonin reuptake inhibitors may be helpful in most patients with stroke // Stroke. 2012. Vol. 43, № 11. P. 3150-3151.
  8. González H.M., Tarraf W., Whitfield K., Gallo J.J. Vascular depression prevalence and epidemiology in the United States // J. Psychiatr. Res. 2012. Vol. 46, № 4. P. 456-461.
  9. Jorge R.E., Acion L., Moser D. et al. Escitalopram and enhancement of cognitive recovery following stroke // Arch. Gen. Psychiatry. 2010. Vol. 67, № 2. P. 187-196.
  10. Krishnan K.R., Taylor W.D., McQuoid D.R. et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression // Biological Psychiatry. 2004. Vol. 55. P. 390-397.
  11. Lee C.H., Park J.H., Yoo K.Y. et al. Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress // Exp. Neurol. 2011. Vol. 229, № 2. P. 450-459.
  12. Lee Y.C., Lin C.H., Lin M.S. et al. Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study // J. Clin. Psychopharmacol. 2013. Vol. 33, № 6. P. 782-789.
  13. Mavrides N., Nemeroff C. Treatment of depression in cardiovascular disease // Depress. Anxiety. 2013. Vol. 30, № 4. P. 328-341.
  14. Mead G.E., Hsieh C.F., Lee R. et al. Selective serotonin reuptake inhibitors for stroke recovery: a systematic review and meta-analysis // Stroke. 2013. Vol. 44, № 3. P. 844-850.
  15. Mikami K., Jorge R.E., Moser D.J. et al. Prevention of poststroke apathy using escitalopram or problem-solving therapy // Am. J. Geriatr. Psychiatry. 2013. Vol. 21, № 9. P. 855-862.
  16. Pimontel M.A., Reinlieb M.E., Johnert L.C. et al. The external validity of MRI-defined vascular depression // Int. J. Geriatr. Psychiatry. 2013. Vol. 28, № 11. P. 1189-1196.
  17. Robinson R.G., Jorge R.E., Moser D.J. et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial // JAMA. 2008. Vol. 299, № 20. P. 2391-2400.
  18. Serra-Millàs M., López-Vílchez I., Navarro V. et al. Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression // Psychopharmacology (Berl). 2011. Vol. 216, № 1. P. 1-8.
  19. Sneed J.R., Roose S.P., Sackeim H.A. Vascular depression: A distinct diagnostic subtype? // Biol. Psychiatry. 2006. Vol. 60, № 12. P. 1295-1298.
  20. Sneed J.R., Rindskopf D., Steffens D.C. et al. The vascular depression subtype: evidence of internal validity // Biol. Psychiatry. 2008. Vol. 64, № 6. P. 491-497.
  21. Sneed J.R., Culang-Reinlieb M.E. The vascular depression hypothesis: an update // Am. J. Geriatr. Psychiatry. 2011. Vol. 19, № 2. P. 99-103.
  22. Stewart J.C., Perkins A.J., Callahan C.M. Effect of collaborative care for depression on risk of cardiovascular events: data from the IMPACT randomized controlled trial // Psychosom. Med. 2014. Vol. 76, № 1. P. 29-37.
  23. Wittchen H.U., Jacobi F., Rehm J. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010 // Eur. Neuropsychopharmacol. 2011. Vol. 21, № 9. P. 655-679.

Copyright (c) 2015 Pribytkov A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies